FDA Okays First Biosimilar for Multiple Sclerosis : vimarsan

Sandoz's natalizumab-sztn injection (Tyruko) is on par with Biogen's Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.

Related Keywords

Paulr Lee , , Drug Administration , Division Of Neurology , Drug Evaluation , Medscape Medical News , Eastern European , Expanded Disability Status Scale , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Biosimilars , Biosimilar Drugs , Follow On Biologics , Secondary Progressive Multiple Sclerosis , Pms , Biologic Therapy , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Clinically Isolated Syndrome , Crohns Disease , Progressive Multifocal ,